In uremic patients, the pharmacokinetics of drugs can be significantly altered. The decreased renal clearance leads to prolonged half-lives of drugs that are normally excreted by the kidneys. This necessitates dosage adjustments to prevent drug toxicity. Additionally, the presence of uremic toxins can interfere with cytochrome P450 enzymes in the liver, further complicating drug metabolism.
